Investors

Profile

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Seven registration studies are currently advancing related to six Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics).

Array BioPharma 2017 Annual Report

Stock Quote & Chart

ARRY (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$11.08
Change (%) Stock is Down 0.26 (2.29%)
Volume1,791,018
Data as of 10/20/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
 
Stock chart for: 03NA000000ARRY
Recent NewsMore >>

Upcoming Events

More >>
There are currently no events scheduled.
Primary IR Contacts
Jason Haddock
Chief Financial Officer
E-mail: ir@arraybiopharma.com

Tricia Haugeto
Director, Corporate Communications and Investor Relations
Phone: (303) 386-1193
E-mail: Tricia.Haugeto@arraybiopharma.com

Transfer Agent
American Stock Transfer and Trust Company
6201 15th Avenue
Brooklyn, NY 11219
Phone: (800) 937-5449
Fax: (718) 236-4588
E-mail: Info@amstock.com
Website: http://www.amstock.com

Legal
Ballard Spahr LLP
5480 Valmont Road, Suite 200
Boulder, CO 80301
Phone: (303) 379-2275

Accountants
KPMG LLP
707 Seventeenth Street, Suite 2700
Denver, CO 80202
Phone: (303) 295-5572


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.